We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Dynamic Trends Seen in Clinical Laboratory Services

By LabMedica International staff writers
Posted on 20 Jan 2014
Print article
The constant pressure to reduce healthcare spending is shifting healthcare utilization in favor of the laboratory. Approximately 80% of physicians' diagnoses are a result of laboratory tests, and a number of these tests are sent to clinical lab service providers. Kalorama Information (New York, NY, USA) has published a new report based on a research study of the market for clinical lab services.

A trend towards preventive and risk factor testing is noted in several disciplines, particularly in the areas of oncology, endocrinology, and gynecology. Physicians in these areas are taking advantage of testing for early detection and disease prevention. Key market data provided includes hospital, physician, and independent lab statistics, major tests performed by clinical lab companies, disease incidence, trends driving lab business, and a market forecast to 2018. The geographic breakout of the clinical lab services market includes the US, Europe and Asia, and specific breakouts for Germany, Japan, China, India, and Brazil.

Some of the other issues and trends explored in the report include US demographics, types of specialty tests, growing competition, increasing life expectancy, the growing incidence of disease, and developments in personalized medicine.

A competitive analysis of leading clinical laboratory providers includes Quest Diagnostics, Inc., Laboratory Corporation of America, Genomic Health, Genoptix, Genzyme Corporation, DaVita, Clarient, Spectra Labs, and Bio-Reference Labs.

The most important part of Kalorama's efforts is its analysis of company activities and their significance in the marketplace. Historical data is provided for the years 2008–2012, with forecast data provided for 2013 through 2017. A competitive analysis is provided for the year 2013. The predicted market analysis for 2013–2017 was largely based on demographic trends, new developments, company performance trends, mergers and acquisitions, and national expansion.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more